Exelixis
| Formerly | Exelixis Pharmaceuticals, Inc. (1994-2000) |
|---|---|
| Type | Public |
| Industry | Biotechnology |
| Founded | November 1994 |
| Headquarters | Alameda, California, U.S. |
| Key people | Stelios Papadopoulos, Ph.D. (chairman) Michael M. Morrissey, Ph.D. (president & CEO) |
| Revenue | |
| Total assets | |
| Total equity | |
Number of employees | 1,077 (2025) |
| Website | exelixis |
| Footnotes | |
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.